Association of Semaglutide With Tobacco Use Disorder in Patients With Type 2 Diabetes : Target Trial Emulation Using Real-World Data.

Publication Date: 2024 Aug


Full Text Sources

Atypon

Ovid Technologies, Inc.

Related Articles


Authors

William Wang; Nora D Volkow; Nathan A Berger; Pamela B Davis; David C Kaelber; Rong Xu

Abstract

OBJECTIVE

Reports of reduced desire to smoke in patients treated with semaglutide, a glucagon-like peptide receptor agonist (GLP-1RA) medication for type 2 diabetes mellitus (T2DM) and obesity, have raised interest about its potential benefit for tobacco use disorders (TUDs).


Source

Annals of internal medicine


Pub Types(s)

Journal Article


Language

English


PubMed ID

39074369